AGP
REGN icon

Artia Global Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Artia Global Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,671
Closed -$6M – 69
2025
Q3 		$6M Hold
10,671
– – 0.95% 18
2025
Q2 		$5.6M Buy
+10,671
New +$5.96M 1.35% 15

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Artia Global Partners's REGN Position: Q4 2025 in Review

Artia Global Partners sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 10,671 shares — an estimated $6M sold.

Artia Global Partners first reported a position in REGN in Q2 2025 and held it in 2 quarters. The position peaked at $6M in Q3 2025. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Artia Global Partners reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Artia Global Partners sold 10,671 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $6M.
  • Artia Global Partners first reported a position in Regeneron Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Artia Global Partners's Regeneron Pharmaceuticals position peaked at $6M in Q3 2025.
  • 1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Artia Global Partners's 13F filing for Q4 2025, filed 17 Feb 2026.